par Abdel Azim, Hatem Hamdy 
;Abdel Azim, Hatem Hamdy
Référence Expert review of anticancer therapy, 13, 2, page (195-201)
Publication Publié, 2013-02
;Abdel Azim, Hatem Hamdy Référence Expert review of anticancer therapy, 13, 2, page (195-201)
Publication Publié, 2013-02
Article révisé par les pairs
| Résumé : | In breast cancer, RANK ligand (RANKL) appears to play an important role in the process of chemotaxis between circulating tumor cells and the bone microenvironment, which enables RANK-expressing breast cancer cells to migrate into the bone. Mounting clinical evidence has further demonstrated that the anti-RANKL monoclonal antibody; denosumab is the most effective approach in the prevention of skeletal-related events. On the other hand, inhibiting RANKL in preclinical models, not only reduced breast cancer formation but also decreased the development of lung metastases, suggesting RANKL as a novel target for breast cancer chemoprevention. In addition, recent data have pointed to a potential role of RANKL in the biology of breast cancer arising at a young age. Hence, RANKL emerges as a key molecule, not only in the field of breast cancer bone metastasis but also in the biology of breast cancer as a whole. |
